Lewis Raymond J
Known title: DirectorCIK: 0001215187
Associated companies
Transaction History
| SBRA | ▲ Buy | Grant | 789 | $0 | 11/30/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 628 | $0 | 8/31/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 789 | $0 | 11/30/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 628 | $0 | 8/31/2021 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sabra Health Care REIT analysts lower price targets
UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.
Sabra Health Care REIT analysts lower price targets. UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.